Infections are an important issue in systemic lupus erythematosus (SLE) patients and account for 30-50% of mortality and morbidity [1-5]. Both cellular and humoral immunity defects [6] and the use of corticosteroids and immunosuppressant agents [7,8] make these patients more susceptible to pathogens. Most infectious processes result from common microorganisms such as bacteria and viruses [9]. I...

Fungal infections have historically been, and remain important causes of transplant-related morbidity in recipients of hematopoietic stem cell transplant (HSCT). However, there have been notable changes in the epidemiology and outcomes of invasive fungal infections, induced by changes in the transplant procedures as well as supportive care. This review discusses invasive fungal infections in he...

Since the 1990s, opportunistic fungal infections have emerged as a substantial cause of morbidity and mortality in profoundly immunocompromised patients. Hypercortisolaemic patients, both those with endogenous Cushing's syndrome and, much more frequently, those receiving exogenous glucocorticoid therapy, are especially at risk of such infections. This vulnerability is attributed to the complex ...

Morbidity and mortality from invasive fungal infections remain unacceptably high despite availability of new antifungal agents, underscoring the need for more effective preventative strategies. Due to our enhanced understanding of the host defense and pathogenetic mechanisms that lead to invasive fungal infections, it should be feasible to develop vaccines targeting these infections. A common i...

The past two decades have seen a considerable increase in both frequency and importance of opportunistic invasive fungal infections in pediatric hospitals. At the same time, major advances have been made in the diagnosis of fungal diseases, the development of algorithms of antifungal interventions, and the design and implementation of pediatric clinical trials. Most importantly, several new ant...